[{"id":"72596fa1-a0d4-4a25-9d18-6edd6d556738","acronym":"","url":"https://clinicaltrials.gov/study/NCT05505825","created_at":"2024-03-25T18:36:13.170Z","updated_at":"2024-07-02T16:35:01.060Z","phase":"Phase 1/2","brief_title":"A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer","source_id_and_acronym":"NCT05505825","lead_sponsor":"Akeso","biomarkers":" ATRX","pipe":" | ","alterations":" ATRX mutation","tags":["ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kaitanni (cadonilimab) • Auraza (chiauranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/26/2022","start_date":" 08/26/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-24"},{"id":"caba8d6b-3a99-4cf4-a5f0-d1c3cfbe3575","acronym":"","url":"https://clinicaltrials.gov/study/NCT03343197","created_at":"2021-01-18T16:30:40.675Z","updated_at":"2024-07-02T16:35:17.668Z","phase":"Phase 1","brief_title":"Study of AG-120 and AG-881 in Subjects With Low Grade Glioma","source_id_and_acronym":"NCT03343197","lead_sponsor":"Institut de Recherches Internationales Servier","biomarkers":" IDH1 • ATRX","pipe":" | ","alterations":" ATRX mutation • IDH1 R132H • IDH1 R132","tags":["IDH1 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation • IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tibsovo (ivosidenib) • Voranigo (vorasidenib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 03/20/2018","start_date":" 03/20/2018","primary_txt":" Primary completion: 08/02/2019","primary_completion_date":" 08/02/2019","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-02-26"},{"id":"e7603ed6-5e6f-419a-8bfc-ae608e45f0bf","acronym":"BRACeD","url":"https://clinicaltrials.gov/study/NCT04038502","created_at":"2021-01-18T19:48:50.249Z","updated_at":"2024-07-02T16:35:30.850Z","phase":"Phase 2","brief_title":"Carboplatin or Olaparib for BRcA Deficient Prostate Cancer","source_id_and_acronym":"NCT04038502 - BRACeD","lead_sponsor":"VA Office of Research and Development","biomarkers":" RAD51B • RAD51C • RAD51D • RAD54L","pipe":" | ","alterations":" ATRX mutation • RAD54L mutation • RAD51 mutation","tags":["RAD51B • RAD51C • RAD51D • RAD54L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation • RAD54L mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 08/29/2025","study_completion_date":" 08/29/2025","last_update_posted":"2023-11-01"},{"id":"12b373a9-f27e-4aa8-b2c5-2cb259826f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03718091","created_at":"2021-01-18T18:13:18.198Z","updated_at":"2024-07-02T16:35:43.598Z","phase":"Phase 2","brief_title":"M6620 (VX-970) in Selected Solid Tumors","source_id_and_acronym":"NCT03718091","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2023-07-07"},{"id":"7cfa6f26-875f-4193-9aef-c545fb2ab82d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03554707","created_at":"2021-01-18T17:29:50.207Z","updated_at":"2024-07-02T16:36:17.444Z","phase":"Phase 1","brief_title":"SGT-53 in Children With Recurrent or Progressive CNS Malignancies","source_id_and_acronym":"NCT03554707","lead_sponsor":"SynerGene Therapeutics, Inc.","biomarkers":" MGMT • MDM2 • CDKN1A","pipe":" | ","alterations":" ATRX mutation • MDM2 mutation","tags":["MGMT • MDM2 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation • MDM2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide • irinotecan • Onivyde (nanoliposomal irinotecan) • SGT-53"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-02-08"},{"id":"4089d77e-fd91-4665-b6b6-7746742e0a38","acronym":"","url":"https://clinicaltrials.gov/study/NCT03750890","created_at":"2021-01-18T18:23:27.032Z","updated_at":"2024-07-02T16:37:01.335Z","phase":"","brief_title":"Visual Study of Molecular Genotype in Glioma Evolution","source_id_and_acronym":"NCT03750890","lead_sponsor":"Tongji Hospital","biomarkers":" EGFR • TP53 • PTEN • MGMT • TERT • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • PTEN mutation • ATRX mutation • TERT mutation • EGFR mutation + PTEN mutation","tags":["EGFR • TP53 • PTEN • MGMT • TERT • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • PTEN mutation • ATRX mutation • TERT mutation • EGFR mutation + PTEN mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2019-03-26"}]